<DOC>
	<DOCNO>NCT01368757</DOCNO>
	<brief_summary>In phase I study investigator plan investigate safety toxicity lenalidomide patient Chronic Myelomonocytic Leukemia ( CMML ) . A phase II study start optimal dose find . The primary endpoint concern efficacy lenalidomide patient CMML accord WHO diagnostic criterion .</brief_summary>
	<brief_title>Lenalidomide Patients With Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . CMML accord WHO diagnostic criterion . 2 . Understand voluntarily sign informed consent form . 3 . Age &gt; =18 year time signing informed consent form . 4 . Able adhere study visit schedule protocol requirement . 5 . All previous cancer therapy must discontinue least 4 week prior treatment study . Patients carry somatic mutation involve platelet derive growth factor receptor beta ( PDGFRB ) include standard treatment imatinib fail . 6 . ECOG performance status &lt; = 2 study entry . 7 . Laboratory test result within range : Creatinine clearance &gt; 30ml/min AST ( SGOT ) ALT ( SGPT ) &lt; = 2.5 x ULN 8 . Disease free prior malignancy &gt; = 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . 9 . Female subject childbearing potential must : Understand study drug expect teratogenic risk Agree use two effective contraception 10 . Male subject must Agree use condom Agree donate semen 11 . All subject must Agree abstain donate blood Agree share study drug another person 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Use experimental drug therapy within 28 day baseline . 5 . Known hypersensitivity thalidomide . 6 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 7 . Any prior use lenalidomide . 8 . Concurrent use anticancer agent treatment . 9 . Known positive HIV infectious hepatitis , type A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Chronic myelomonocytic leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
</DOC>